Advances in dorzolamide hydrochloride delivery: harnessing nanotechnology for enhanced ocular drug delivery in glaucoma management
Source abstract
Abstract
Dorzolamide hydrochloride (DRZ) is a carbonic anhydrase inhibitor utilized in managing elevated intraocular pressure (IOP) associated with glaucoma. However, its clinical effectiveness is hindered by a short half-life, low residence time, and the need for frequent dosing, highlighting the necessity for innovative delivery systems. This work reviews recent advancements in DRZ delivery, particularly focusing on cyclodextrin complexation and nanotechnology applications. It explores the potential of cyclodextrin derivatives to enhance DRZ's bioavailability. DRZ cyclodextrin complexes or nanoparticulate systems maintain high drug concentrations in the eye while minimizing irritation and viscosity-related issues. Nanotechnology introduces nanoparticle-based carriers such as polymeric nanoparticles, solid lipid nanoparticles, liposomes, niosomes, and nanoemulsions. These formulations enable sustained drug release, improved corneal permeation, and enhanced patient compliance. Clinical trials have shown that DRZ nanoparticle eye drops and nanoliposome formulations offer efficacy comparable to conventional therapies, with the potential for better tolerability. Overall, this review highlights significant progress in DRZ delivery systems, suggesting their potential to transform glaucoma treatment by addressing current limitations and improving therapeutic outcomes.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Glaucoma and retinal disorders · Ocular Surface and Contact Lens · Advanced Drug Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (88)
Show source-provided references
1. Loftsson T, Jansook P, Stefánsson E. Topical drug delivery to the eye: dorzolamide. Acta Ophthalmol. 2012;90:603–8. https://doi.org/10.1111/j.1755-3768.2011.02299.x.10.1111/j.1755-3768.2011.02299.x ↗
2. Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma. JAMA. 2014;311:1901. https://doi.org/10.1001/jama.2014.3192.10.1001/jama.2014.3192 ↗
3. Yoo H-S, Shanmugalingam U, Smith PD. Harnessing astrocytes and müller glial cells in the retina for survival and regeneration of retinal ganglion cells. Cells. 2021;10:1339. https://doi.org/10.3390/cells10061339.10.3390/cells10061339 ↗
4. Tribble JR, Hui F, Quintero H, et al. Neuroprotection in glaucoma: mechanisms beyond intraocular pressure lowering. Mol Aspects Med. 2023;92:101193. https://doi.org/10.1016/j.mam.2023.101193.10.1016/j.mam.2023.101193 ↗
5. García-Llorca A, Carta F, Supuran CT, Eysteinsson T. Carbonic anhydrase, its inhibitors and vascular function. Front Mol Biosci. 2024. https://doi.org/10.3389/fmolb.2024.1338528.10.3389/fmolb.2024.1338528 ↗
6. Capasso C, Supuran CT. Carbonic anhydrase and bacterial metabolism: a chance for antibacterial drug discovery. Expert Opin Ther Pat. 2024. https://doi.org/10.1080/135437762332663.10.1080/135437762332663 ↗
7. Patton GN, Lee HJ. Chemical insights into topical agents in intraocular pressure management: from glaucoma etiopathology to therapeutic approaches. Pharmaceutics. 2024;16:274. https://doi.org/10.3390/pharmaceutics16020274.10.3390/pharmaceutics16020274 ↗
8. Maren TH. Role of carbonic anhydrase in aqueous humour and cerebrospinal fluid formation. In: Barriers and fluids of the eye and brain. London: Macmillan Education UK; 1992. p. 37–48.10.1007/978-1-349-12306-3_5 ↗
9. Schmidl D, Schmetterer L, Garhöfer G, Popa-Cherecheanu A. Pharmacotherapy of Glaucoma. J Ocul Pharmacol Ther. 2015;31:63–77. https://doi.org/10.1089/jop.2014.0067.10.1089/jop.2014.0067 ↗
10. Supuran CT. A simple yet multifaceted 90 years old, evergreen enzyme: Carbonic anhydrase, its inhibition and activation. Bioorg Med Chem Lett. 2023;93:129411. https://doi.org/10.1016/j.bmcl.2023.129411.10.1016/j.bmcl.2023.129411 ↗
11. Dartt DA. Neural regulation of lacrimal gland secretory processes: Relevance in dry eye diseases. Prog Retin Eye Res. 2009;28:155–77. https://doi.org/10.1016/j.preteyeres.2009.04.003.10.1016/j.preteyeres.2009.04.003 ↗
12. Balfour JA, Wilde MI. Dorzolamide. Drugs Aging. 1997;10:384–403. https://doi.org/10.2165/00002512-199710050-00006.10.2165/00002512-199710050-00006 ↗
13. Purkerson JM, Schwartz GJ. The role of carbonic anhydrases in renal physiology. Kidney Int. 2007;71:103–15. https://doi.org/10.1038/sj.ki.5002020.10.1038/sj.ki.5002020 ↗
14. Stoner A, Harris A, Oddone F, et al. Topical carbonic anhydrase inhibitors and glaucoma in 2021: where do we stand? Br J Ophthalmol. 2022;106:1332–7. https://doi.org/10.1136/bjophthalmol-2021-319530.10.1136/bjophthalmol-2021-319530 ↗
15. Jansook P, Hnin HM, Loftsson T, Stefánsson E. Cyclodextrin-based formulation of carbonic anhydrase inhibitors for ocular delivery – a review. Int J Pharm. 2021;606:120955. https://doi.org/10.1016/j.ijpharm.2021.120955.10.1016/j.ijpharm.2021.120955 ↗
16. Agarwal R, Gupta S, Agarwal P, et al. Current concepts in the pathophysiology of glaucoma. Indian J Ophthalmol. 2009;57:257. https://doi.org/10.4103/0301-4738.53049.10.4103/0301-4738.53049 ↗
17. Inoue J, Oka M, Aoyama Y, et al. Effects of dorzolamide hydrochloride on ocular tissues. J Ocul Pharmacol Ther. 2004;20:1–13. https://doi.org/10.1089/108076804772745419.10.1089/108076804772745419 ↗
18. Dietrich UM, Chandler MJ, Cooper T, et al. Effects of topical 2% dorzolamide hydrochloride alone and in combination with 0.5% timolol maleate on intraocular pressure in normal feline eyes. Vet Ophthalmol. 2007;10:95–100. https://doi.org/10.1111/j.1463-5224.2007.00583.x.10.1111/j.1463-5224.2007.00583.x ↗
19. Kobayashi M, Naito K. Pharmacological profiles of the potent carbonic anhydrase inhibitor dorzolamide hydrochloride, a topical antiglaucoma agent. Folia Pharmacol Jpn. 2000;115:323–8. https://doi.org/10.1254/fpj.115.323.10.1254/fpj.115.323 ↗
20. Wang Y-C, Ling XC, Tsai W-H, et al. Risks of topical carbonic anhydrase inhibitors in glaucoma patients with chronic kidney disease: a nationwide population-based study. Am J Ophthalmol. 2023;253:49–55. https://doi.org/10.1016/j.ajo.2023.05.007.10.1016/j.ajo.2023.05.007 ↗
21. Ghorai S, Pulya S, Ghosh K, et al. Structure-activity relationship of human carbonic anhydrase-II inhibitors: detailed insight for future development as anti-glaucoma agents. Bioorg Chem. 2020;95:103557. https://doi.org/10.1016/j.bioorg.2019.103557.10.1016/j.bioorg.2019.103557 ↗
22. Di FA, De SG, Menchise V, et al. Carbonic anhydrase inhibitors: X-ray crystal structure of a benzenesulfonamide strong CA II and CA IX inhibitor bearing a pentafluorophenylaminothioureido tail in complex with isozyme II. Bioorg Med Chem Lett. 2005;15:1937–42. https://doi.org/10.1016/j.bmcl.2005.01.086.10.1016/j.bmcl.2005.01.086 ↗
23. Vedani A, Meyer EF. Structure-activity relationships of sulfonamide drugs and human carbonic anhydrase C: modeling of inhibitor molecules into the receptor site of the enzyme with an interactive computer graphics display1. J Pharm Sci. 1984;73:352–8. https://doi.org/10.1002/jps.2600730316.10.1002/jps.2600730316 ↗
24. Baldwin JJ, Ponticello GS, Anderson PS, et al. Thienothiopyran-2-sulfonamides: novel topically active carbonic anhydrase inhibitors for the treatment of glaucoma. J Med Chem. 1989;32:2510–3. https://doi.org/10.1021/jm00132a003.10.1021/jm00132a003 ↗
25. Paganini V, Chetoni P, Di Gangi M, et al. Nanomicellar eye drops: a review of recent advances. Expert Opin Drug Deliv. 2024. https://doi.org/10.1080/174252472323208.10.1080/174252472323208 ↗
26. Jin K, Li Y, Wu H, et al. Integration of smartphone technology and artificial intelligence for advanced ophthalmic care: a systematic review. Adv Ophthalmol Pract Res. 2024. https://doi.org/10.1016/j.aopr.2024.03.003.10.1016/j.aopr.2024.03.003 ↗
27. Ezike TC, Okpala US, Onoja UL, et al. Advances in drug delivery systems, challenges and future directions. Heliyon. 2023;9:e17488. https://doi.org/10.1016/j.heliyon.2023.e17488.10.1016/j.heliyon.2023.e17488 ↗
28. Schopf LR, Popov AM, Enlow EM, et al. Topical ocular drug delivery to the back of the eye by mucus-penetrating particles. Transl Vis Sci Technol. 2015;4:11. https://doi.org/10.1167/tvst.4.3.11.10.1167/tvst.4.3.11 ↗
29. Kagkelaris K, Panayiotakopoulos G, Georgakopoulos CD. Nanotechnology-based formulations to amplify intraocular bioavailability. Ther Adv Ophthalmol. 2022;14:251584142211123. https://doi.org/10.1177/25158414221112356.10.1177/25158414221112356 ↗
30. Ahmed S, Amin MM, Sayed S. Ocular drug delivery: a comprehensive review. AAPS PharmSciTech. 2023;24:66. https://doi.org/10.1208/s12249-023-02516-9.10.1208/s12249-023-02516-9 ↗
31. del Amo EM, Rimpelä A-K, Heikkinen E, et al. Pharmacokinetic aspects of retinal drug delivery. Prog Retin Eye Res. 2017;57:134–85. https://doi.org/10.1016/j.preteyeres.2016.12.001.10.1016/j.preteyeres.2016.12.001 ↗
32. Agarwal P, Craig JP, Rupenthal ID. Formulation considerations for the management of dry eye disease. Pharmaceutics. 2021;13:207. https://doi.org/10.3390/pharmaceutics13020207.10.3390/pharmaceutics13020207 ↗
33. Pardeshi SR, More MP, Kulkarni AD, et al. Current perspectives in nanomedicine delivery for targeted ocular therapeutics. Bull Mater Sci. 2023;46:35. https://doi.org/10.1007/s12034-022-02869-0.10.1007/s12034-022-02869-0 ↗
34. Subrizi A, del Amo EM, Korzhikov-Vlakh V, et al. Design principles of ocular drug delivery systems: importance of drug payload, release rate, and material properties. Drug Discov Today. 2019;24:1446–57. https://doi.org/10.1016/j.drudis.2019.02.001.10.1016/j.drudis.2019.02.001 ↗
35. Tau J, Passerini MS, del Papa M, et al. A novel ophthalmic latanoprost 0.005% nanoemulsion: a cytotoxicity study. Graefe’s Arch Clin Exp Ophthalmol. 2022;260:1941–6. https://doi.org/10.1007/s00417-021-05536-y.10.1007/s00417-021-05536-y ↗
36. Kassem AA, Salama A, Mohsen AM. Formulation and optimization of cationic nanoemulsions for enhanced ocular delivery of dorzolamide hydrochloride using Box-Behnken design: in vitro and in vivo assessments. J Drug Deliv Sci Technol. 2022;68:103047. https://doi.org/10.1016/j.jddst.2021.103047.10.1016/j.jddst.2021.103047 ↗
37. Guo X, Zhang J, Liu X, et al. Antioxidant nanoemulsion loaded with latanoprost enables highly effective glaucoma treatment. J Control Release. 2023;361:534–46. https://doi.org/10.1016/j.jconrel.2023.08.004.10.1016/j.jconrel.2023.08.004 ↗
38. Londhe VY, Sharma S. Formulation, characterization, optimization and in-vivo evaluation of methazolamide liposomal in-situ gel for treating glaucoma. J Drug Deliv Sci Technol. 2022;67:102951. https://doi.org/10.1016/j.jddst.2021.102951.10.1016/j.jddst.2021.102951 ↗
39. Brugnera M, Vicario-de-la-Torre M, González-Cela Casamayor MA, et al. Enhancing the hypotensive effect of latanoprost by combining synthetic phosphatidylcholine liposomes with hyaluronic acid and osmoprotective agents. Drug Deliv Transl Res. 2024. https://doi.org/10.1007/s13346-024-01584-z.10.1007/s13346-024-01584-z ↗
40. Vicario-de-la-Torre M, Benitez-del-Castillo JM, Vico E, et al. Design and characterization of an ocular topical liposomal preparation to replenish the lipids of the tear film. Invest Ophthalmol Vis Sci. 2014;55:7839–47. https://doi.org/10.1167/iovs.14-14700.10.1167/iovs.14-14700 ↗
41. El-Feky YA, Fares AR, Zayed G, et al. Repurposing of nifedipine loaded in situ ophthalmic gel as a novel approach for glaucoma treatment. Biomed Pharmacother. 2021;142:112008. https://doi.org/10.1016/j.biopha.2021.112008.10.1016/j.biopha.2021.112008 ↗
42. Nair AB, Shah J, Jacob S, et al. Experimental design, formulation and in vivo evaluation of a novel topical in situ gel system to treat ocular infections. PLoS ONE. 2021;16:e0248857. https://doi.org/10.1371/journal.pone.0248857.10.1371/journal.pone.0248857 ↗
43. Makwana SB, Patel VA, Parmar SJ. Development and characterization of in-situ gel for ophthalmic formulation containing ciprofloxacin hydrochloride. Results Pharma Sci. 2016;6:1–6. https://doi.org/10.1016/j.rinphs.2015.06.001.10.1016/j.rinphs.2015.06.001 ↗
44. Agarwal P, Rupenthal ID. Non-aqueous formulations in topical ocular drug delivery – A paradigm shift? Adv Drug Deliv Rev. 2023;198:114867. https://doi.org/10.1016/j.addr.2023.114867.10.1016/j.addr.2023.114867 ↗
45. Wang C, Pang Y. Nano-based eye drop: topical and noninvasive therapy for ocular diseases. Adv Drug Deliv Rev. 2023;194:114721. https://doi.org/10.1016/j.addr.2023.114721.10.1016/j.addr.2023.114721 ↗
46. Naik JB, Pardeshi SR, Patil RP, et al. Mucoadhesive micro-/nano carriers in ophthalmic drug delivery: an overview. Bionanoscience. 2020;10:564–82. https://doi.org/10.1007/s12668-020-00752-y.10.1007/s12668-020-00752-y ↗
47. Patel KD, Barrios Silva L, Park Y, et al. Recent advances in drug delivery systems for glaucoma treatment. Mater Today Nano. 2022;18:100178. https://doi.org/10.1016/j.mtnano.2022.100178.10.1016/j.mtnano.2022.100178 ↗
48. Jansook P, Stefánsson E, Thorsteinsdóttir M, et al. Cyclodextrin solubilization of carbonic anhydrase inhibitor drugs: formulation of dorzolamide eye drop microparticle suspension. Eur J Pharm Biopharm. 2010;76:208–14. https://doi.org/10.1016/j.ejpb.2010.07.005.10.1016/j.ejpb.2010.07.005 ↗
49. Park CG, Kim YK, Kim S-N, et al. Enhanced ocular efficacy of topically-delivered dorzolamide with nanostructured mucoadhesive microparticles. Int J Pharm. 2017;522:66–73. https://doi.org/10.1016/j.ijpharm.2017.02.035.10.1016/j.ijpharm.2017.02.035 ↗
50. Fu J, Sun F, Liu W, et al. Subconjunctival delivery of dorzolamide-loaded poly(ether-anhydride) microparticles produces sustained lowering of intraocular pressure in rabbits. Mol Pharm. 2016;13:2987–95. https://doi.org/10.1021/acs.molpharmaceut.6b00343.10.1021/acs.molpharmaceut.6b00343 ↗
51. Katiyar S, Pandit J, Mondal RS, et al. In situ gelling dorzolamide loaded chitosan nanoparticles for the treatment of glaucoma. Carbohydr Polym. 2014;102:117–24. https://doi.org/10.1016/j.carbpol.2013.10.079.10.1016/j.carbpol.2013.10.079 ↗
52. Papadimitriou S, Bikiaris D, Avgoustakis K, et al. Chitosan nanoparticles loaded with dorzolamide and pramipexole. Carbohydr Polym. 2008;73:44–54. https://doi.org/10.1016/j.carbpol.2007.11.007.10.1016/j.carbpol.2007.11.007 ↗
53. Shinde U, Ahmed MH, Singh K. Development of dorzolamide loaded 6-O -carboxymethyl chitosan nanoparticles for open angle glaucoma. J Drug Deliv. 2013;2013:1–15. https://doi.org/10.1155/2013/562727.10.1155/2013/562727 ↗
54. Shahab MS, Rizwanullah M, Alshehri S, Imam SS. Optimization to development of chitosan decorated polycaprolactone nanoparticles for improved ocular delivery of dorzolamide: in vitro, ex vivo and toxicity assessments. Int J Biol Macromol. 2020;163:2392–404. https://doi.org/10.1016/j.ijbiomac.2020.09.185.10.1016/j.ijbiomac.2020.09.185 ↗
55. Warsi MH, Anwar M, Garg V, et al. Dorzolamide-loaded PLGA/vitamin E TPGS nanoparticles for glaucoma therapy: Pharmacoscintigraphy study and evaluation of extended ocular hypotensive effect in rabbits. Colloids Surf B Biointerfaces. 2014;122:423–31. https://doi.org/10.1016/j.colsurfb.2014.07.004.10.1016/j.colsurfb.2014.07.004 ↗
56. Manchanda S, Sahoo PK. Fabrication and characterization of mucoadhesive topical nanoformulations of dorzolamide HCl for ocular hypertension. J Pharm Investig. 2018;48:323–32. https://doi.org/10.1007/s40005-017-0324-x.10.1007/s40005-017-0324-x ↗
57. Shahab MS, Rizwanullah M, Sarim Imam S. Formulation, optimization and evaluation of vitamin E TPGS emulsified dorzolamide solid lipid nanoparticles. J Drug Deliv Sci Technol. 2022;68:103062. https://doi.org/10.1016/j.jddst.2021.103062.10.1016/j.jddst.2021.103062 ↗
58. Afify EAMR, Elsayed I, Gad MK, et al. Enhancement of pharmacokinetic and pharmacological behavior of ocular dorzolamide after factorial optimization of self-assembled nanostructures. PLoS ONE. 2018;13:e0191415. https://doi.org/10.1371/journal.pone.0191415.10.1371/journal.pone.0191415 ↗
59. Kouchak M, Malekahmadi M, Bavarsad N, et al. Dorzolamide nanoliposome as a long action ophthalmic delivery system in open angle glaucoma and ocular hypertension patients. Drug Dev Ind Pharm. 2018;44:1239–42. https://doi.org/10.1080/03639045.2017.1386196.10.1080/03639045.2017.1386196 ↗
60. Franca JR, Foureaux G, Fuscaldi LL, et al. Chitosan/hydroxyethyl cellulose inserts for sustained-release of dorzolamide for glaucoma treatment: In vitro and in vivo evaluation. Int J Pharm. 2019;570:118662. https://doi.org/10.1016/j.ijpharm.2019.118662.10.1016/j.ijpharm.2019.118662 ↗
61. Özdemir S, Çakirli E, Sürücü B, et al. Preparation and characterization studies of dorzolamide-loaded ophthalmic implants for treating glaucoma. Turkish J Pharm Sci. 2023;20:149–56. https://doi.org/10.4274/tjps.galenos.2022.95752.10.4274/tjps.galenos.2022.95752 ↗
62. Patil SS, Bade A, Tagalpallewar A. Design, optimization and pharmacodynamic comparison of dorzolamide hydrochloride soluble ocular drug insert prepared by using 3 2 factorial design. J Drug Deliv Sci Technol. 2018;46:138–47. https://doi.org/10.1016/j.jddst.2018.05.010.10.1016/j.jddst.2018.05.010 ↗
63. Pardeshi SR, More MP, Pardeshi CV, et al. Novel crosslinked nanoparticles of chitosan oligosaccharide and dextran sulfate for ocular administration of dorzolamide against glaucoma. J Drug Deliv Sci Technol. 2023;86:104719. https://doi.org/10.1016/j.jddst.2023.104719.10.1016/j.jddst.2023.104719 ↗
64. Sahoo S, Dilnawaz F, Krishnakumar S. Nanotechnology in ocular drug delivery. Drug Discov Today. 2008;13:144–51. https://doi.org/10.1016/j.drudis.2007.10.021.10.1016/j.drudis.2007.10.021 ↗
65. Paolicelli P, de la Fuente M, Sánchez A, et al. Chitosan nanoparticles for drug delivery to the eye. Expert Opin Drug Deliv. 2009;6:239–53. https://doi.org/10.1517/17425240902762818.10.1517/17425240902762818 ↗
66. Arabestani MR, Bigham A, Kamarehei F, et al. Solid lipid nanoparticles and their application in the treatment of bacterial infectious diseases. Biomed Pharmacother. 2024;174:116433. https://doi.org/10.1016/j.biopha.2024.116433.10.1016/j.biopha.2024.116433 ↗
67. Pham CV, Cho C-W. Application of d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) in transdermal and topical drug delivery systems (TDDS). J Pharm Investig. 2017;47:111–21. https://doi.org/10.1007/s40005-016-0300-x.10.1007/s40005-016-0300-x ↗
68. Mohammed HA, Khan RA, Singh V, et al. Solid lipid nanoparticles for targeted natural and synthetic drugs delivery in high-incidence cancers, and other diseases: roles of preparation methods, lipid composition, transitional stability, and release profiles in nanocarriers’ development. Nanotechnol Rev. 2023. https://doi.org/10.1515/ntrev-2022-0517.10.1515/ntrev-2022-0517 ↗
69. Alkholief M, Albasit H, Alhowyan A, et al. Employing a PLGA-TPGS based nanoparticle to improve the ocular delivery of acyclovir. Saudi Pharm J. 2019;27:293–302. https://doi.org/10.1016/j.jsps.2018.11.011.10.1016/j.jsps.2018.11.011 ↗
70. Manca ML, Aroffu M, Fulgheri F, et al. Conventional methods for preparing liposomes of various types (MLVs, LUVs, SUVs). In: Liposomes in Drug Delivery. Amsterdam: Elsevier; 2024. p. 461–88.10.1016/B978-0-443-15491-1.00011-0 ↗
71. Nii T, Ishii F. Encapsulation efficiency of water-soluble and insoluble drugs in liposomes prepared by the microencapsulation vesicle method. Int J Pharm. 2005;298:198–205. https://doi.org/10.1016/j.ijpharm.2005.04.029.10.1016/j.ijpharm.2005.04.029 ↗
72. Paramshetti S, Angolkar M, Talath S, et al. Unravelling the in vivo dynamics of liposomes: Insights into biodistribution and cellular membrane interactions. Life Sci. 2024;346:122616. https://doi.org/10.1016/j.lfs.2024.122616.10.1016/j.lfs.2024.122616 ↗
73. Biswas A, Kumar S, Choudhury AD, et al. Polymers and their engineered analogues for ocular drug delivery: enhancing therapeutic precision. Biopolymers. 2024. https://doi.org/10.1002/bip.23578.10.1002/bip.23578 ↗
74. Tasharrofi N, Nourozi M, Marzban A. How liposomes pave the way for ocular drug delivery after topical administration. J Drug Deliv Sci Technol. 2022;67:103045. https://doi.org/10.1016/j.jddst.2021.103045.10.1016/j.jddst.2021.103045 ↗
75. Kouchak M, Bahmandar R, Bavarsad N, Farrahi F. Ocular dorzolamide nanoliposomes for prolonged IOP reduction: in-vitroand in-vivo evaluation in rabbits. Iran J Pharm Res IJPR. 2016;15:205–12.
76. Sharma A, Singh M, Sharma V, et al. Current paradigms in employing self-assembled structures: drug delivery implications with improved therapeutic potential. Colloids Surf B Biointerfaces. 2024;234:113745. https://doi.org/10.1016/j.colsurfb.2024.113745.10.1016/j.colsurfb.2024.113745 ↗
77. Liu Y, Castro Bravo KM, Liu J. Targeted liposomal drug delivery: a nanoscience and biophysical perspective. Nanoscale Horizons. 2021;6:78–94. https://doi.org/10.1039/D0NH00605J.10.1039/D0NH00605J ↗
78. Alyami H, Abdelaziz K, Dahmash EZ, Iyire A. Nonionic surfactant vesicles (niosomes) for ocular drug delivery: development, evaluation and toxicological profiling. J Drug Deliv Sci Technol. 2020;60:102069. https://doi.org/10.1016/j.jddst.2020.102069.10.1016/j.jddst.2020.102069 ↗
79. Moammeri A, Chegeni MM, Sahrayi H, et al. Current advances in niosomes applications for drug delivery and cancer treatment. Mater Today Bio. 2023;23:100837. https://doi.org/10.1016/j.mtbio.2023.100837.10.1016/j.mtbio.2023.100837 ↗
80. Hasan AA. Design and in vitro characterization of small unilamellar niosomes as ophthalmic carrier of dorzolamide hydrochloride. Pharm Dev Technol. 2014;19:748–54. https://doi.org/10.3109/10837450.2013.829095.10.3109/10837450.2013.829095 ↗
81. Hashemi Dehaghi M, Haeri A, Keshvari H, et al. Dorzolamide loaded niosomal vesicles: comparison of passive and remote loading methods. Iran J Pharm Res IJPR. 2017;16:413–22.
82. Gawin-Mikołajewicz A, Nartowski KP, Dyba AJ, et al. Ophthalmic nanoemulsions: from composition to technological processes and quality control. Mol Pharm. 2021;18:3719–40. https://doi.org/10.1021/acs.molpharmaceut.1c00650.10.1021/acs.molpharmaceut.1c00650 ↗
83. Ammar HO, Salama HA, Ghorab M, Mahmoud AA. Nanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride. AAPS PharmSciTech. 2009;10:808. https://doi.org/10.1208/s12249-009-9268-4.10.1208/s12249-009-9268-4 ↗
84. Gorantla S, Rapalli VK, Waghule T, et al. Nanocarriers for ocular drug delivery: current status and translational opportunity. RSC Adv. 2020;10:27835–55. https://doi.org/10.1039/D0RA04971A.10.1039/D0RA04971A ↗
85. Asendrych-Wicik K, Zarczuk J, Walaszek K, et al. Trends in development and quality assessment of pharmaceutical formulations - F2α analogues in the glaucoma treatment. Eur J Pharm Sci. 2023;180:106315. https://doi.org/10.1016/j.ejps.2022.106315.10.1016/j.ejps.2022.106315 ↗
86. Gudmundsdottir BS, Petursdottir D, Asgrimsdottir GM, et al. γ-Cyclodextrin nanoparticle eye drops with dorzolamide: effect on intraocular pressure in man. J Ocul Pharmacol Ther. 2014;30:35–41. https://doi.org/10.1089/jop.2013.0060.10.1089/jop.2013.0060 ↗
87. ClinicalTrials.gov (2023) ClinicalTrials.gov. In: ClinicalTrials.gov
88. Google Patents (2024)